The power of partnerships - a word from our director
Public-private partnerships draw on the diverse expertise, capabilities and roles of research organisations, companies, healthcare bodies, national agencies, and civil society organisations to drive projects that no single organisation can tackle alone.
This past month we have seen the power of these partnerships in tackling important issues in health research – advancing new clinical trials to bring new treatment options for children with type 1 diabetes, delivering promising new molecules for drug-resistant tuberculosis, and developing early screening diagnostics for Alzheimer’s disease.
This year we had great success with our applicant-led call 9 – bringing new ideas and new organisations into the programme. Our next call, call 12, builds on this success – we have a short article with a heads up and information on our upcoming brokerage event.
Building a successful partnership is hard – finding an idea and organising a work plan that creates value for all partners require time and effort. Our advice to IHI applicants is to start early, build lasting networks, listen, and share ideas – and our brokerage event is the perfect place to do all of these things! Register today – and start preparing your ideas and partnerships.
Niklas Blomberg, IHI Executive Director
This past month we have seen the power of these partnerships in tackling important issues in health research – advancing new clinical trials to bring new treatment options for children with type 1 diabetes, delivering promising new molecules for drug-resistant tuberculosis, and developing early screening diagnostics for Alzheimer’s disease.
This year we had great success with our applicant-led call 9 – bringing new ideas and new organisations into the programme. Our next call, call 12, builds on this success – we have a short article with a heads up and information on our upcoming brokerage event.
Building a successful partnership is hard – finding an idea and organising a work plan that creates value for all partners require time and effort. Our advice to IHI applicants is to start early, build lasting networks, listen, and share ideas – and our brokerage event is the perfect place to do all of these things! Register today – and start preparing your ideas and partnerships.
Niklas Blomberg, IHI Executive Director
IHI Brokerage Event – registration open
Join us in Brussels on 4-5 November for two days of face-to-face networking and consortium-building for IHI call 12. The event will also feature pitching sessions on project proposals to kick-start consortium building, and poster sessions to showcase potential project partners.
Register here
IHI to continue pioneering applicant-driven approach in next call for proposals
IHI call 12, which is scheduled for launch in early 2026, will invite applicants to explore the IHI Strategic Research and Innovation Agenda and mine it for ideas for ambitious, public-private projects that could transform health research and care.
IHI call 11 – deadline coming soon
IHI call 11 has topics on brain dysfunction, the link between infections and non-communicable diseases, pharmacovigilance, type 1 diabetes, and ambulatory surgical centres. The deadline for short proposals is 9 October.
Sign up for our event on IMI and IHI’s impact on blood cancers
Join us online on 1 October to find out how IMI/IHI projects are leveraging big data and advancing CAR-T cell therapies to improve the care of people living with blood cancers like leukaemia.
Tale of potent anti-TB treatment highlights power of partnerships
A promising and much-needed tuberculosis (TB) treatment is advancing through clinical trials thanks to support from European partnerships IMI2 and EDCTP.
Simple brain scan reveals early signs of Alzheimer’s disease
PREDICTOM used data from electroencephalograms (EEGs) to reveal a slowdown in communication between different brain regions from the earliest stages of Alzheimer’s disease.
Faster, innovative clinical trials for type 1 diabetes treatments proven possible
The minimum effective dose of an off-label diabetes treatment for children and young people was successfully established using an adaptive trial designed by INNODIA.